<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614846</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO- Ie-ITP</org_study_id>
    <nct_id>NCT02614846</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients</brief_title>
  <official_title>A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic
      Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive
      Hetrombopag.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>From Day 1 to Day 70.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Chronic Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Hetrombopag Olamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the subjects receive 6 weeks Hetrombopag Olamine dosing, 5mg for the first 2 weeks, 2.5mg or 7.5mg for the last 4 weeks according to the PLT counting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine</intervention_name>
    <arm_group_label>Hetrombopag Olamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria:

               1. Confirmed diagnosis of chronic ITP,a peripheral blood smear or bone marrow
                  examination should support the diagnosis of ITP with no evidence of other causes
                  of thrombocytopenia.

               2. Patients had a platelet count of less than 30,000/µL both in the screening period
                  and baseline.

               3. Subjects who are refractory or have relapsed after at least one prior ITP
                  therapy.

               4. Previous therapy for ITP including rescue must have been completed at least 2
                  weeks prior to randomization.

               5. Subjects treated with maintenance immunosuppressive therapy must be receiving a
                  dose that has been stable for at least 1 month.

               6. A complete blood count (CBC), within the reference range, with the following
                  exceptions.

          -  Platelets &lt;30×109/L is required for inclusion .

          -  Hemoglobin: females and males 10.0 g/dl are eligible for inclusion.

          -  Absolute neutrophil count (ANC) ≥1500/µL (1.5×109/L) is required for inclusion.

             7.PT result no exceed normal by more than ±3s,APTT result no exceed normal by more
             than ±10s.

             8.Female subjects have a negative result with HCG testing in the screening period and
             baseline.

          -  Exclusion Criteria:

               1. Patients with any prior history of arterial or venous thrombosis，or diagnosis as
                  Thrombophilia.

               2. Subjects diagnosed with tumor.

               3. Have pre-existing cardiac disease within the last 3 months.No arrhythmia known to
                  increase the risk of thrombolic events (e.g. atrial fibrillation), or patients
                  with a Corrected QT interval (QTc) &gt;450msec or QTc &gt;480 for patients with a
                  Bundle Branch Block.

               4. Female subjects who are nursing or pregnant at screening or pre-dose on baseline.

               5. Treatment with thrombopoietin or an investigational drug within 30 days or five
                  half-lives (whichever is longer) preceding the first dose of study medication.

               6. Treatment with Rituximab or Splenectomy within the lat 6 months.

               7. Subjects who have previously received eltrombopag or any other thrombopoietin
                  receptor agonist within 30 days or five half-lives (whichever is longer).

               8. Subject has consumed aspirin, aspirin-containing compounds, salicylates,
                  anticoagulants, quinine or non-steroidal anti-inflammatories (NSAIDs) for &gt;3
                  consecutive days within 2 weeks of the study start and until the end of the
                  study.

               9. Any laboratory or clinical evidence for HIV infection.Any clinical history for
                  hepatitis C infection; chronic hepatitis B infection; or any evidence for active
                  hepatitis at the time of subject screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yu Hu, Ph.D</last_name>
    <email>dr_huyu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heng Mei, Ph.D</last_name>
    <email>mayheng@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Hu, Ph.D</last_name>
      <email>dr_huyu@126.com</email>
    </contact>
    <investigator>
      <last_name>Yu Hu, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>November 22, 2015</last_update_submitted>
  <last_update_submitted_qc>November 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

